Abstract: The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-octadecanoyloxytetradecanoylamino]-&bgr;-D-glucopyranosyl]-2-[(R)-3-hexadecanoyloxytetradecanoylamino]-D-glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.
Type:
Grant
Filed:
August 10, 2001
Date of Patent:
June 4, 2002
Assignee:
Corixa Corporation
Inventors:
Gary T. Elliott, Patricia A. Weber, C. Gregory Sowell
Abstract: Synthetic low molecular weight catalysts for the dismutation of superoxide are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions such as arthritis, and also operate to prevent or reverse tolerance to opioid analgesics.
Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lympho-cytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1-X[Fuc&agr;1-y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration and for directing molecules to such sites.
Type:
Grant
Filed:
November 9, 1994
Date of Patent:
May 21, 2002
Assignees:
Stanford University
Inventors:
John L. Magnani, Eugene C. Butcher, Ellen L. Berg
Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1−X[Fuc&agr;1−y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.
Type:
Grant
Filed:
November 9, 1994
Date of Patent:
May 14, 2002
Assignees:
Stanford University
Inventors:
John L. Magnani, Eugene C. Butcher, Ellen L. Berg
Abstract: Compositions of heparins of very low molecular weight, with the formula I, in which, n may vary between 1 and 12; R1=H or SO3Na; R2=SO3Na or COCH3. Such compositions of heparin are composed of mixtures of oligosaccharides or fragments of heparin and are characterised by having anti-Xa activity and anti-factor IIa activity and because they can be used as anti-thrombic medicaments.
Abstract: The present invention provides illudin analogs of the general formula (I):
where
R1 is (CH2)n—X—Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C1-C8)alkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C4)alkyl or cyclo(C3-C6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4;
R2 is absent; or R1 and R2 together comprise a 5-7 membered cyclic ring;
R3 is (C1-C4)alkyl or H; R4 is H, SCH2CO2 (C1-C4)alkyl, O—(C5-C12)aryl or —S—(C5-C12)aryl; R5 is H, OH or absent; R6 is (C1-C4)alkyl or absent; R7 is OH or OSi((C1-C4)alkyl)3; or
R6 and R7 together are ethylenedioxy;
R8 is optionally substituted (C1-C4)alkyl; and
the bonds represented by ----- are individually present or absent. The invention further provides dimers comprising analogs of formula (I).
Abstract: Catechol derivatives of general formula (I)
in which R1 denotes O-acyl and R2 represents amino acid residues in the 3- and/or 4-position function as siderophores and/or as biological chelating agents for iron in gram-negative bacteria. Conjugates with antibiotics improve penetration into bacterial cells, thereby increasing antibacterial efficacy of the cells.
Abstract: Disclosed are novel coumarin based fluorogenic compounds useful in assaying for biological activity. Specifically, these fluorogenic compounds exhibit fluorescence at particular wavelengths when cleaved by target enzymes. Preferred compounds include sugar and peptide derivatives of umbelliferone derivatives bearing a heterocyclic five membered ring at the 3-position. These compounds can be used for rapidly detecting food pathogens and for determining sterilization effectiveness. The compounds may also be used in a form bounded to a polymeric support or to a biomolecule or macromolecule.
Type:
Grant
Filed:
July 7, 2000
Date of Patent:
April 16, 2002
Assignee:
3M Innovative Properties Company
Inventors:
James Gregory Bentsen, Christopher Allen Mickelson, Orlin Bruce Knudson, Kevin Michael Lewandowski
Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure
wherein
Y is C or N;
where n is 0-3;
X is
R1, and R2 are each independently, hydrogen, alkyl of 1 to 6 carbon atoms, halo, acetyl, phenyl, CF3, CN, OH, NO2, NH2, alkoxy of 1 to 6 carbon atoms, or alkoxynitrile of 1 to 6 carbon atoms;
R3 is hydrogen, acylamide of 2 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms;
R4, R5, R6, R7, and R8 are each, independently, acyl of 1 to 6 carbon atoms, benzyl substituted with R1, and R2; or benzoyl substituted with R1 and R2;
R9 and R10 are each, independently, acyl of 1 to 6 carbon atoms, or the R9 and R10 groups on the 4′ and 6′ positions of the maltose may be taken together to form a cyclic acetal which may be substituted with alkyl of 1 to 6 carbon atoms, two alkyl groups each having 1 to 6 carbon atoms, pyridine substituted with R1, phenyl substituted with R1, benzyl substituted with R1, 2-phenylethyl substituted
Abstract: This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.
Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure
wherein
Y is C or N;
where n is 0-3;
X is
R1, and R2 are independently, hydrogen, alkyl of 1 to 6 carbon atoms, or halo, acetyl, phenyl, CF3, CN, OH, NO2, NH2, alkoxy of 1 to 6 carbon atoms, or cyanoalkoxy of 2 to 7 carbon atoms;
R3 is hydrogen, acylamide of 2 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms;
R4, R5, R6, R7, and R8 are each, independently, acyl of 1 to 6 carbon atoms, benzyl substituted with R1, and R2; or benzoyl substituted with R1 and R2;
R9 and R10 are each, independently, acyl of 1 to 6 carbon atoms, or the R9 and R10 groups on the 4′ and 6′ positions of the maltose may be taken together to form a cyclic acetal which may be substituted with alkyl of 1 to 6 carbon atoms, two alkyl groups each having 1 to 6 carbon atoms, pyridine substituted with R1, phenyl substituted with R1, benzyl substituted with R1, 2-phenylethyl substituted wit
Abstract: Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from E. coli, cholera toxin, clostridium difficile toxins A and B, bacterial pili from enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) and viral lectins such as viral hemagglutinins. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves.
Type:
Grant
Filed:
May 24, 1999
Date of Patent:
October 30, 2001
Assignee:
Governors of the University of Alberta
Inventors:
David R. Bundle, Pavel Kitov, Randy J. Read, Hong Ling, Glen Armstrong
Abstract: The present invention provides for an isolated A-type substance having a structure identical to an A-type substance obtained from human liver or placenta, which is a cyclical containing carbohydrate comprising Zn2+ and related compositions.
Abstract: A variety of compounds are provided which are useful as immunogens and as tumor markers. The present invention discloses methods relating to the detection of cancer. Extended forms of the lacto-series type 1 chain are shown to be present in various cancer tissues. The present invention also provides a cell line and the monoclonal antibody produced therefrom. Such an antibody has a number of uses, including in diagnostic or therapeutic methods.
Type:
Grant
Filed:
March 22, 1999
Date of Patent:
September 25, 2001
Assignee:
The Biomembrane Institute
Inventors:
Steven B. Levery, Sen-itiroh Hakomori, Mark R Stroud
Abstract: The invention relates to a method of preparing a compound of the following formula:
wherein each of R1, R2, R3, and R4, independently, is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, heteroaryl, aralkyl, heteroaralkyl, haloalkyl, or alkyloxyalkyl, provided that R1 and R2, optionally form a keto or, with the carbon atom to which they are attached, optionally form a cyclic moiety, and that R3 and R41, optionally form a keto or, with the carbon atom to which they are attached, optionally form a cyclic moiety.
Abstract: An injectable composition is provided for promoting bone and/or cartilage growth comprising hyaluronic acid cross-linked to sulfated polysaccharide through linking groups. The linking groups are diamines or amino polyalkylene glycols. The sulfated polysaccharide binds growth factors suitable for promoting tissue growth at the site of application of the composition.
Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1&agr;, IL-1&bgr; and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.
Abstract: The present invention discloses carbohydrates and carbohydrate analogs that bind to epidermal growth factor (EGF) receptors. Methods of using such carbohydrates or analogs for a variety of uses related to the EGF receptor are also provided. In preferred aspects of the present invention, methods for killing or inhibiting the growth of tumor cells with increased EGF receptor activity are disclosed.
Abstract: Disclosed and claimed are: a composition including at least one glycosaminoglycan, e.g., CIS, and at least one alginate, e.g., sodium alginate, wherein:
the at least one glycosaminoglycan and/or the algninate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt; or
the at least one glycosaminoglycan and the alginate are covalently bound, e.g., by means of a coupling reaction involving a linker molecule such as DVS; or
the at least one glycosaminoglycan and/or the algninate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt, and the at least one glycosaminoglycan and the alginate are covalently bound, e.g.
Abstract: The present invention provides for an isolated P-type substance having a structure identical to a P-type substance obtained from human liver or placenta, which is a cyclitol containing carbohydrate comprising Mn2+ and Zn2+ and related compositions.